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There is growing evidence that inﬂammation may be one of the causal factors of osteoporosis. Several cytokines such as IL-1,
IL-6, RANKL, OPG, and M-CSF were implicated in the pathogenesis of osteoporosis. These cytokines are important determinants
of osteoclast diﬀerentiation and its bone resorptive activity. Anticytokine therapy using cytokine antagonists such as IL-receptor
antagonist and TNF-binding protein was able to suppress the activity of the respective cytokines and prevent bone loss. Several
animal studies have shown that vitamin E in the forms of palm-derived tocotrienol and α-tocopherol may prevent osteoporosis
in rat models by suppressing IL-1 and IL-6. Free radicals are known to activate transcription factor NFκB which leads to the
production of bone resorbing cytokines. Vitamin E, a potent antioxidant, may be able to neutralise free radicals before they could
activate NFκB, therefore suppressing cytokine production and osteoporosis. Vitamin E has also been shown to inhibit COX-2, the
enzymeinvolvedininﬂammatoryreactions.OfthetwotypesofvitaminEstudied,tocotrienolseemedtobebetterthantocopherol
in terms of its ability to suppress bone-resorbing cytokines.
1.Introduction
Osteoporosis is a bone disease, characterized by low bone
mass and increased risk of fractures [1]. It is well accepted
that osteoporosis can be caused by various endocrine,
metabolic, and mechanical factors. However, recently, there
are opinions that there may be an inﬂammatory component
in the etiology of osteoporosis [2, 3]. There is plenty of evi-
dencelinkinginﬂammationtoosteoporosis.Epidemiological
studies have identiﬁed higher incidence of osteoporosis
in various inﬂammatory conditions such as ankylosing
spondylitis, rheumatoid arthritis, and systemic lupus erythe-
matosus [4–7]. This association was also observed clinically
whereby the degree of osteoporosis was equivalent to the
extent of inﬂammation. If the inﬂammation was systemic,
bone loss will occur at all skeletal sites, whereas if the
inﬂammation was only restricted to a site, bone loss will only
occur locally at that site of inﬂammation [3]. Elderly patients
are more prone to osteoporosis, and this was believed to be
connected to the elevated production of proinﬂammatory
cytokines with aging [8, 9].
The occurrence of inﬂammation is indicated by the
presence of inﬂammatory markers such as cytokines and
C-reactive protein. Biochemical studies have demonstrated
elevation of proinﬂammatory cytokines TNF-α and IL-
6 in arthritic disease such as gouty arthritis, rheumatoid
arthritis, and psoriatic arthritis [10, 11]. An obvious rela-
tionship between inﬂammation and osteoporosis was seen
in rheumatoid arthritis, whereby proinﬂammatory cytokines
were released causing bone loss around the aﬀected joints
[12]. The level of C-reactive protein, a sensitive marker
of systemic inﬂammation, was also found to be associ-
ated with bone mineral density [13]. Inﬂammation may
contribute to bone loss by aﬀecting the bone remodeling
process, favouring bone resorption activity by osteoclasts
rather than bone formation activity by osteoblasts [14, 15].
Bone resorption is determined by the balance between two
cytokines, receptor activator of nuclear factor κBl i g a n d
(RANKL), and osteoprotegerin (OPG) [16]. RANKL is
crucial for the diﬀerentiation and activation of osteoclast
[17]. Higher RANKL levels were associated with lower bone
mineral density in men [18]. Administration of serum2 Advances in Pharmacological Sciences
RANKL to mice promoted osteoclast growth and activation,
leading to osteoporosis [19]. On the other hand, OPG an-
tagonizes RANKL by binding with RANKL and preventing
it from binding to RANK receptors. By doing that, OPG
was able to inhibit osteoclastogenesis and bone resorption
[20]. Macrophage colony stimulating factor (MCSF) is
another important determinant of osteoclastogenesis, but its
mechanism to modulate osteoclastogenesis is still not clear
[20].
The “upstream” cytokines such as IL-1, IL-6, and TNF-
α [21, 22] and “downstream” cytokines such as RANKL,
OPG, and M-CSF [23–25] played an important role in bone
remodeling. Imbalance in their bioactivity may lead to bone
loss and osteoporosis. Cytokines are small- to medium-sized
proteins or glycoproteins with molecular weight ranging
from 8 to 40,000 dalton. They act as the biological mediator
for most cells and function at low concentrations between
10−10 and 10−5 molar. They have a short half-life of less
than 10 minutes, and their serum level can be as low as
10pg/mL. The cytokine levels increase dramatically during
inﬂammation and infection. The measurement of cytokine
levels in close vicinity to bone such as the bone marrow
is important for studies on osteoporosis and other bone
diseases. In postmenopausal women, cytokine production
by the peripheral monocytes correlated well with cytokines
secreted by monocytes in the bone marrow. Therefore,
cytokine levels in the serum are representative of the local
monocytes [26]. Stromal cells and osteoblasts produce
interleukin-1, interleukin-6, and tumor necrosis factor-α.
These proinﬂammatory cytokines are also known as the
bone-resorbing cytokines or proosteoclast cytokines as they
promote osteoclast diﬀerentiation and activity [27–30]. The
bone resorption activity of these cytokines in ovariectomised
rats was reduced with anticytokine therapy such as IL-1
receptor antagonists and TNF-binding protein [31]. Vitamin
E, a potent antioxidant vitamin, was also found to inhibit or
suppress cytokine production [32, 33]. This vitamin E action
may be responsible for its ability to prevent inﬂammation
and osteoporosis, seen in several studies on osteoporosis
using animal models [34].
Vitamin E is a group of potent, lipid-soluble, chain-
breaking antioxidants. It can be classiﬁed into tocopherol
and tocotrienol based on the chemical structure. Palm oil,
which is extracted from the pulp of the fruit of the oil palm
Elaeis guineensis, is abundant in tocotrienols. Tocotrienol
has an unsaturated farnesyl (isoprenoid) side-chain, while
tocopherol has a saturated phytyl side chain [35].
Vitamin E occurs in eight isoforms of α-, β-, γ-, and
δ-tocopherols or tocotrienols. It was thought that both the
γ and δ isomers of tocopherol have better antioxidant and
anti-inﬂammatory activities than the α isomer [36, 37].
Once vitamin E is absorbed in the intestine, it will enter
the circulation via the lymphatic system and be transported
to the liver with the chylomicrons [38]. Vitamin E is me-
tabolized by cytochrome P450 and then excreted in the urine
[39].
In human subjects and animal models, high doses of
vitamin E were found to exhibit anti-inﬂammatory eﬀects
by decreasing C-reactive protein (CRP) and inhibiting the
release of proinﬂammatory cytokines [40]. These were
evident in a study on patients with coronary artery disease,
whereby the CRP and tumor necrosis factor-α (TNF-α)
concentrations were found to be signiﬁcantly lowered with
α-tocopherol supplementation compared to placebo [41].
Since vitamin E was also found to inhibit cyclooxygenase-
2 activities, it was thought to be able to exert anti-in-
ﬂammatory and anticarcinogenic activities, especially in the
colon [42]. This was demonstrated by Yang et al. [43],
who found that vitamin E was able to signiﬁcantly lower
colon inﬂammation index and reduced the number of colon
adenomas in mice given azoxymethane.
This paper will focus on the eﬀects of vitamin E on bone-
resorbing cytokines with special attention on IL-1 and IL-6.
2.Interleukin-1(IL-1)
IL-1 plays an important role in various reactions towards
infection, inﬂammation, and immune activation. This
cytokine is produced by various cells but the main producer
is the monocyte. In the physiological condition, monocytes
do not secrete IL-1 but, under pathological conditions such
as septic shock, IL-1 is rapidly released and acts directly
on the blood vessels. Other cytokines such as TNF-α and
interferon, bacterial endotoxin, virus, and antigen can also
stimulate the release of IL-1. Reactive oxygen species such
as superoxide radicals have been shown to induce IL-1
production [32, 44]. IL-1 is involved in the pathogenesis
of various diseases associated with bone loss such as osteo-
porosis [45, 46], cancer-induced osteolysis [47], rheumatoid
arthritis [48], and osteolysis of orthopedic implants [49]. IL-
1 is also an important factor in both in vivo and in vitro
bone resorption [50, 51]. It stimulates the formation and
activity of osteoclasts, leading to excessive bone resorption.
Suda et al. [52] demonstrated that the presence of osteoblast
and stromal cells was crucial in the formation of osteoclasts
by IL-1. Thomson et al. [53] also reported that osteoblasts
secrete a factor that stimulates the bone-resorbing activities
of rat osteoclasts. However, Xu et al. [54] demonstrated that
rat osteoclasts expressed mRNA to IL-1 receptors, while Yu
and Ferrier [55] found that osteoclast is one of the target
cells for IL-1. These studies proved that IL-1 can act directly
on osteoclasts without the presence of osteoblasts or stromal
cells. IL-1 may also promote formation of osteoclasts [56]. It
acts by activating nuclear factor κB( N F κB) in osteoclast and
prevents its apoptosis [57]. It was found that the estrogen-
deﬁcient state in postmenopausal women or ovariectomised
rats resulted in increased production of IL-1 by monocyte
and other bone marrow cells [58, 59]. Estrogen replacement
or IL-receptor antagonist was able to prevent the elevation
of IL-1 in ovariectomised rats [60, 61]. Vitamin E was also
f o u n dt oh a v et h ea b i l i t yt os u p p r e s sI L - 1p r o d u c t i o nb y
activated monocytes [62]. In a diﬀerent study, combination
of superoxide dismutase and vitamin E was eﬀective in
inhibiting IL-1 production by human monocytes [32]. The
ability of vitamin E to inhibit IL-1 in the bone environment
may have prevented bone loss.Advances in Pharmacological Sciences 3
3.Interleukin-6(IL-6)
IL-6 is another cytokine that is associated with various
pathophysiological processes in humans. It is produced
by the haematopoetic and nonhaematopoetic cells when
they were exposed to various types of stimulation. During
bone remodeling, IL-6 is produced in nanomolar concen-
trations by stromal cells and osteoblasts under the inﬂu-
ence of parathyroid hormone, vitamin D3,g r o w t hf a c t o r ,
and other cytokines [63]. IL-6 was also reported to be
produced by osteoblasts when stimulated by IL-1, TNF-α,
and lipopolysaccharide [64]. McSheeny and Chambers [65]
reported that osteoblasts were stimulated by local IL-1 to
produce IL-6, which was responsible for the activation of
osteoclasts. IL-6 promoted the diﬀerentiation of osteoclasts
from its precursor and played an important role in the
pathogenesis of osteoporosis due to estrogen deﬁciency [66,
67]. The IL-6 elevation in postmenopausal women was
reduced by estrogen replacement therapy [68]. The elevation
of IL-6 may be related to free radical activities especially
reactive oxygen species. Reactive oxygen species was found
to elevate the IL-6 levels directly via activation of nuclear
factor κB( N F κB)[69]. High cytokine levels would also result
in activation of NFκB and promotion of osteoclastogenesis
[70].
4. VitaminE asAnticytokineAgent
The eﬀects of vitamin E on bone resorbing cytokines for
prevention and treatment of osteoporosis have been studied
using FeNTA and nicotine rat models [34, 71]. These
models represent osteoporosis caused by oxidative stress and
smoking, respectively. However, similar studies in humans
are still lacking. Ferric nitrilotriacetate (FeNTA) is an
oxidizing agent which produces free radicals via the Fenton
reaction [72, 73]. Oxidative stress can be induced in rats by
injecting them with FeNTA, allowing the hazardous eﬀects
of free radicals on various organs and tissues including
bone to be studied. The bone resorbing cytokines, IL-1
and IL-6, were found to be elevated in this oxidative stress
rat model, indicating inﬂammation. This was accompanied
by osteoporotic changes as indicated by the measurement
of bone markers and histomorphometric parameters [34].
The elevation of cytokines was probably achieved through
the activation of cytokine-encoding genes like STAT3 or
nuclearfactor-kappaBbythefreeradicals[74,75].Therefore,
there exist relationships between free radicals, inﬂammation,
and bone loss which can lead to osteoporosis. When
vitamin E in the form of tocotrienols and α-tocopherol
were supplemented to these rats, IL-1 and IL-6 elevations
were suppressed. Concurrent with this, the osteoporotic
changes were also inhibited [34, 71, 76]. Therefore, there
is a possibility that vitamin E, a potent antioxidant, has
prevented free radicals from causing inﬂammation and
osteoporosis. Tocotrienols seemed to be more superior than
α-tocopherol in suppressing proinﬂammatory cytokines in
the FeNTA rat model and in protecting their bone against
osteoporosis [34]. Both the tocopherol and tocotrienol may
have achieved this by scavenging the free radicals generated
by FeNTA before they could activate the monocytes and
osteoblasts, cells that produce IL-1 and IL-6.
Cigarettesmokingisamodestriskfactorforosteoporosis
[77]. Nicotine is among the 4,700 chemicals found in the
tar phase of cigarette smoke [78]. Nicotine injected into rats
can be used as a model for osteoporosis related to smoking.
Variousanimalstudieshaveconﬁrmedthedeleteriouseﬀects
of nicotine on bone remodeling [79–85]. Nicotine inhibited
osteoblast activity and growth [86, 87]b u ts t i m u l a t e d
osteoclast activity [83]. Nicotine has also been shown to
induce oxidative stress in both in vitro and in vivo animal
studies [88, 89]. Crowley-Weber et al. [90]h a dr e p o r t e d
that other than oxidative stress, nicotine also activated
nuclear transcription factor-κB( N F - κB) in the tissues of
smokers. The activation of NF-κB-signaling pathway may
be the mechanism for bone loss as it is responsible for
osteoclast diﬀerentiation [76, 91]. Nicotine has been shown
to signiﬁcantly elevate the proinﬂammatory cytokines IL-1
and IL-6 in rats. Using the same model, tocotrienol was able
to prevent nicotine-induced elevation of IL-1 and IL-6, while
tocopherol had no signiﬁcant eﬀects on both cytokines [71].
Tocotrienol was more eﬀective compared to tocopherol in
terms of its action on bone resorbing cytokines and therefore
w a sm o r ee ﬀective in reducing inﬂammation and bone loss.
5. Anti-Inﬂammatory Action of Vitamin E
in Prevention of Osteoporosis
Results from studies on cytokines have given us some insight
on the mechanisms involved in the protection of vitamin
E against osteoporosis. Free radicals are known to activate
transcription factor NFκB which leads to the production
of bone resorbing cytokines interleukin-1 and interleukin-6.
These proinﬂammatory cytokines were believed to provide
the link between inﬂammation and osteoporosis. Vitamin
E may scavenge and neutralize free radicals before they
could activate transcription factor NFκB. This was seen in
an oxidative stress model (FeNTA model) in which vitamin
E had reduced the levels of bone-resorbing cytokines [34].
Alternatively, vitamin E may have prevented the activation
of NFκB by enhancing the internal antioxidative enzymes
within the bone. This was demonstrated by Maniam et
al. [92], whereby vitamin E supplementation reduced the
femoral thiobarbituric acid-reactive substance (TBARS) and
increased the glutathione peroxidase activity.
Since osteoporosis is associated with inﬂammation, there
is also a possibility that Vitamin E may have some anti-
inﬂammatory action. Yam et al. [93] found that tocotrienol
was able to suppress cyclooxygenase-2 (COX-2) expression
in RAW 264.7 cells that were exposed to lipopolysaccharide.
COX-2 is an inducible enzyme expressed during inﬂamma-
tion.ARA Wcellisamacrophage-lik ecellwhichtransformed
into preosteoclasts when RANKL is added. This suggested
that vitamin E may act as anti-inﬂammatory agent in pro-
tecting bone against excessive osteoclastic activity. Previous
study has shown that aspirin or other nonsteroidal anti-
inﬂammatory drugs (NSAID) inhibited NFκB[ 94]. Similar4 Advances in Pharmacological Sciences
to tocotrienol, these anti-inﬂammatory drugs inhibit COX-
2. As the activation of NFκB is linked to proinﬂammatory
cytokines and inﬂammation, it further provides evidence
of the anti-inﬂammatory role of tocotrienol in preventing
osteoporosis.
Based on the results from the studies above, tocotrienol
was more superior than tocopherol in terms of its ability
to suppress bone resorbing cytokines. The more supe-
rior tocotrienol action may be contributed by its more
potent antioxidant property. It has better interaction with
lipoprotein in membrane lipids and is uniformly distributed
in the membrane layer compared to tocopherol [35, 95].
Tocotrienol was also better at maintaining the antioxidant
status within the rat bone compared to tocopherol [92].
Thus, the antiosteoporotic eﬀect of tocotrienol may be partly
explained by its anti-inﬂammatory as well as antioxidative
eﬀects.
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